Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 36
  1. Apr 09, 2026 · 07:01 · SVA

    “Debt‑free pivot fuels balance‑sheet rebuild as Sernova clears inherited liabilities”

    Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

    01
  2. Apr 09, 2026 · 07:00 · LSL

    Juno OTC secures Loratadine RDT partnership, expanding Canadian OTC pipeline

    JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA

    02
  3. Apr 09, 2026 · 07:00 · AIAI

    NetraMark’s quantum‑brain paper adds scientific cache but no immediate financial upside

    Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

    03
  4. Apr 08, 2026 · 19:33 · 4565

    Nxera’s GPCR platform hits second Lilly milestone, unlocking up to $694 M in future upside

    Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

    04
  5. Apr 08, 2026 · 17:22 · BETR

    “Tiny $500K private placement adds cash but deepens dilution for BETR‑001 pipeline”

    Betterlife Pharma arranges $500,000 private placement

    05
  6. Apr 08, 2026 · 16:31 · MRVL

    Small convertible debenture adds cash but raises dilution risk amid mounting debt

    Marvel Biosciences Announces Proposed Convertible Debenture Offering

    06
  7. Apr 08, 2026 · 12:18 · MYTC

    “Liquidity collapse forces MyndTec into insolvency review, casting doubt on any near‑term recovery.”

    MyndTec Inc. Announces Inability to Secure Financing, Cessation of Operations and Evaluation of Strategic Alternatives Including Insolvency Proceedings

    07
  8. Apr 08, 2026 · 12:14 · ADK

    Regulatory timeline update keeps CARA on track, no surprise for investors

    DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA

    08
  9. Apr 08, 2026 · 08:00 · AIDR

    Expanding into Maryland adds a new payer‑network foothold, but follows an already aggressive U.S. rollout

    Rocket Doctor Announces Maryland Expansion and Strategic Appointment of New Medical Lead

    09
  10. Apr 08, 2026 · 07:00 · BLCO

    FDA clearance lifts Bausch + Lomb’s surgical toolkit, but market impact stays modest

    Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+(TM) Dual-Port Vitrectomy Cutter and Adaptive Fluidics(TM) Advanced Update

    10
  11. Apr 07, 2026 · 18:18 · JUMP

    LevelJump secures $750k bridge financing, staving off cash crunch and keeping growth runway intact

    LevelJump Announces Non-Brokered Private Placement

    11
  12. Apr 07, 2026 · 09:18 · NRX

    “Strategic LOI with BioXtek could fast‑track U.S. exosome manufacturing and de‑risk clinical rollout”

    NurExone Biologic's U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

    12
  13. Apr 07, 2026 · 08:18 · SONA

    Preclinical combo of THT and PD‑1 shows durable tumor clearance, reinforcing pipeline momentum

    Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study

    13
  14. Apr 07, 2026 · 07:30 · MRVL

    New strategic financing trims Phase I cash burn, nudging MB‑204 toward first‑in‑human trial

    Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures

    14
← Newer Older →